



Media Release
1 February 23

OPTISCAN ACCELERATING MOMENTUM IN 2023 WITH REFRESHED BRANDING, NEW TEAM & EXCITING AI DEVELOPMENT

Optiscan Imaging this week announced an exclusive collaboration with Canadian based Prolucid Technologies to develop Artificial Intelligence (AI) algorithms and telepathology workflows using its confocal laser endomicroscopy (CLE) technology.

The project, anticipated to take 18-24 months, and will eventually develop a software as a medical device (SaMD) using Optiscan's unique platform technology. The results will support image collection, processing, and tissue analytics to detect the presence of pre-cancerous and cancerous cells, enabling immediate clinical decision-making.

The exclusive partnership with Prolucid puts Melbourne-based Optiscan at the forefront of AI innovation, and combined with the Company's cutting-edge slide-free, biopsy-free live digital imaging technology, forms part of a broader strategy.

The refreshed branding and new management team appointed in 2022 sees Optiscan transition into a pure-play medical company in 2023, with specific focus on:

1. Launching **InVivage®**, its first clinical screening device, into the US market.
2. Building **clinical evidence** for application of its technology in new large addressable markets, such as breast cancer.
3. Accelerating **innovation**, next generation hardware upgrades and optical innovations.
4. Growing the **ViewnVivo®** life sciences research device.

Optiscan CEO and Managing Director, Dr. Camile Farah stated, "The development of AI algorithms with Prolucid aligns with our vision to be at the forefront of enabling immediate, informed clinical decisions for clinicians using digital microscopy. Our telepathology platform will allow remote diagnosis and assist with the uptake of our imaging platform in addition to opening new revenue streams. We are excited about accelerating our momentum in 2023, and bringing our slide-free, biopsy-free optical technology to the world".

– ends –

For media queries, please contact:

Andrew Barker

Marketing & Communications Manager – Optiscan Imaging Ltd

E: abarker@optiscan.com

About Optiscan

Optiscan Imaging Ltd (ASX:OIL) is a global leader in the development, manufacturing, and commercialisation of confocal endomicroscopic imaging technologies for medical, translational and pre-clinical applications. Our technology enables real-time, non-destructive, 3D, *in-vivo* imaging at the single cell level.

We are driven by developing technology and its use to give healthcare providers and researchers the highest quality real-time microscopic imaging tools to enable the early detection and management of disease, improve patient outcomes, and reduce the high cost of curative medicine and associated procedures.

Our patent-protected proprietary technology, using specially miniaturised componentry, has created a pen-sized digital microscope, which can be used on any tissue it contacts to produce high resolution digital pathology images for cancer diagnosis and surgical margin detection in real-time. The aim of our technology development is for earlier diagnosis and subsequent treatment of cancerous tumours with expected associated improved patient outcomes.

Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as ‘anticipate’, ‘believe’, ‘could’, ‘estimate’, ‘expect’, ‘future’, ‘intend’, ‘may’, ‘opportunity’, ‘plan’, ‘potential’, ‘project’, ‘seek’, ‘will’ and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.

P: (61 3) 9538 3333

A: 16 Miles St, Mulgrave VIC 3170, Australia

W: www.optiscan.com